


CLAIMS


We claim:

1. A method of preparing a compound of formula (V):




- 5 the method comprising:

(a) contacting ethyl isobutyrate with a substituted 5-chloropentane in the presence of a first base to form a compound of formula (I):




10 wherein the substituted 5-chloropentane is selected from the group consisting of 1-bromo-5-chloropentane and 1-iodo-5-chloropentane;

(b) contacting the compound of formula (I) with a salt of formula $[M]^+[X]^-$ to form a compound of formula (II):



15 wherein $[M]^+$ is selected from the group consisting of Li^+ , Na^+ and K^+ , and $[X]^-$ is selected from the group consisting of Br^- and I^- ;

(c) contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide in the presence of a second base to form a first intermediate, and contacting the first intermediate with an acid to form a compound of formula (IV):



20 (d) contacting the compound of formula (IV) with a reducing agent to form a second intermediate, and contacting the second intermediate with a hydrolyzing base to form a compound of formula (V).

2. The method of claim 1, wherein in step (a), the first base is selected from the group

consisting of lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium hydride, sodium amide, lithium amide, and lithium tetramethylpiperidide.

3. The method of claim 1 or 2, wherein in step (a), contacting ethyl isobutyrate with the substituted 5-chloropentane is conducted at a temperature in the range of about -20 °C to about 5 0 °C.
4. The method of any one of claims 1-3, wherein in step (a), less than about 1% by weight of the substituted 5-chloropentane remains after forming the compound of formula (I).
5. The method of any one of claims 1-4, wherein in step (a), the molar ratio of ethyl isobutyrate to the substituted 5-chloropentane is from about 1.1:1 to about 1.21:1.
- 10 6. The method of any one of claims 1-5, wherein in step (b), contacting the compound of formula (I) with the salt of formula $[M]^+[X]^-$ is conducted in a solvent comprising one or more of acetone, 2-butanone, methyl isobutyl ketone, and tetrahydrofuran, wherein M is selected from the group consisting of Li, Na and K, and X is selected from the group consisting of Br and I.
- 15 7. The method of claim 6, wherein in step (b), the solvent comprises less than about 3% by weight water.
8. The method of any one of claims 1-7, wherein in step (b), contacting the compound of formula (I) with the salt of formula $[M]^+[X]^-$ is conducted at a temperature in the range of about 78 °C to about 82 °C, wherein M is selected from the group consisting of Li, Na and K, and X 20 is selected from the group consisting of Br and I.
9. The method of any one of claims 1-8, wherein in step (b), contacting the compound of formula (I) with the salt of formula $[M]^+[X]^-$ comprises contacting the compound of formula (I) with about 1.1 molar equivalents of the salt of formula $[M]^+[X]^-$ based on the molar amount of the compound of formula (I), wherein M is selected from the group consisting of Li, Na and K, 25 and X is selected from the group consisting of Br and I.
10. The method of any one of claims 1-9, wherein in step (b), the salt of formula $[M]^+[X]^-$ is sodium iodide.
11. The method of any one of claims 1-10, wherein in step (c), the second base is selected

from sodium hydride, potassium tert-butoxide, and sodium tert-pentoxide.

12. The method of any one of claims 1-11, wherein in step (c), contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide in the presence of a second base to form the first intermediate is conducted at a temperature in a range of about -20 °C to about 10 °C.

5 13. The method of any one of claims 1-12, wherein in step (c), the molar ratio of the compound of formula (II) to toluenesulfonylmethyl isocyanide is about 1.9:1.

14. The method of any one of claims 1-13, wherein in step (c), contacting the compound of formula (II) with toluenesulfonylmethyl isocyanide is conducted in dimethylacetamide.

15. The method of any one of claims 1-14, wherein in step (c), contacting the first
10 intermediate with an acid is conducted at a temperature in a range of about -10 °C to about 35 °C.

16. The method of any one of claims 1-15, wherein in step (c), the acid is hydrochloric acid.

17. The method of any one of claims 1-16, wherein in step (d), the reducing agent is selected from the group consisting of sodium borohydride, sodium cyanoborohydride, cerium
15 borohydride, zinc borohydride and diisobutylaluminum hydride.

18. The method of any one of claims 1-17, wherein in step (d), contacting the compound of formula (IV) with a reducing agent comprises contacting the compound of formula (IV) with about 0.35 molar equivalents of the reducing agent based on the molar amount of the compound of formula (IV).

20 19. The method of any one of claims 1-18, wherein in step (d), the hydrolyzing base is sodium hydroxide.

20. The method of any one of claims 1-19, wherein in step (d), contacting the second intermediate with a hydrolyzing base to form a compound of formula (V) is conducted in a solution; and the method further comprises adjusting the pH of the solution comprising the
25 compound of formula (V) to between about 3 to about 7.

21. The method of any one of claims 1-20, wherein in step (d), contacting the compound of formula (IV) with a reducing agent to form a second intermediate, and contacting the second

intermediate with a hydrolyzing base to form a compound of formula (V) is conducted in a single reaction vessel.

22. The method of any one of claims 1-21, further comprising:

5 (e) purifying the compound of formula (V) to provide a pharmaceutical material comprising a purified amount of the compound of formula (V).

23. The method of claim 22, wherein in step (e), purifying the compound of formula (V) comprises filtering the compound of formula (V) in a solvent through silica gel.

24. The method of claim 22 or 23, wherein in step (e), purifying the compound of formula (V) comprises crystallizing the compound of formula (V).

10 25. The method of any one of claims 22-24, wherein in step (e), purifying the compound of formula (V) comprises crystallizing the compound of formula (V) from a solvent, wherein the solvent comprises ethyl acetate.

15 26. The method of any one of claims 22-25, wherein in step (e), purifying the compound of formula (V) comprises crystallizing the compound of formula (V) from a mixture of solvents, wherein the mixture of solvents comprises ethyl acetate and water.

27. The method of any one of claims 22-26, wherein in step (e), purifying the compound of formula (V) comprises crystallizing the compound of formula (V) to provide a crystalline form of the compound of formula (V), and the method further comprises recrystallizing the crystalline form of the compound of formula (V).


20 28. The method of claim 27, wherein crystallizing the compound of formula (V) and recrystallizing the crystalline form of the compound of formula (V) comprise crystallizing the compound of formula (V) in a mixture of solvents comprising ethyl acetate and water, and recrystallizing the crystalline form of the compound of formula (V) in a mixture of solvents comprising ethyl acetate and water.

25 29. The method of any one of claims 22-28, further comprising purifying the compound of formula (V) by contacting the compound of formula (V) with charcoal and then filtering the charcoal.

30. The method of any one of claims 22-29, wherein the purified amount of the compound


of formula (V) is greater than 99.0% by weight of the total weight of the pharmaceutical material.

31. A method of preparing a compound of formula (V):




5 the method comprising:


(a) contacting 1-bromo-5-chloropentane with about 1.1 molar equivalents of ethyl isobutyrate in the presence of lithium diisopropylamide at a temperature in the range of about -20 °C to about 0 °C to form a compound of formula (I):



10 (b) contacting the compound of formula (I) with about 1.1 molar equivalents of sodium iodide in 2-butanone at a temperature in the range of about 78 °C to about 82 °C to form a compound of formula (IIa):



15 (c) contacting the compound of formula (IIa) with toluenesulfonylmethyl isocyanide in the presence of sodium tert-pentoxide in dimethylacetamide at a temperature in the range of about -20 °C to about 10 °C to form a first intermediate, and contacting the first intermediate with an acid at a temperature in the range of about -10 °C to about 35 °C to form a compound of formula (IV):



20 (d) contacting the compound of formula (IV) with about 0.35 molar equivalents of sodium borohydride to form a second intermediate, and contacting the second intermediate with sodium hydroxide in a solution to form a compound of formula (V).

32. The method of claim 31, wherein in step (c), the molar ratio of the compound of formula (IIa) to toluenesulfonylmethyl isocyanide to sodium tert-pentoxide is about 1.9:1:2.1.

33. The method of claim 31 or 32, further comprising:

(f) adjusting the pH of the solution comprising the compound of formula (V) to about 5 to about 6;

(g) extracting the compound of formula (V) from the solution using methyl tert-butyl ether to provide a methyl tert-butyl ether solution comprising the compound of formula (V);

(h) exchanging the methyl tert-butyl ether of the methyl tert-butyl ether solution with ethyl acetate to provide an ethyl acetate solution comprising the compound of formula (V);

(i) filtering the ethyl acetate solution comprising the compound of formula (V) through silica gel;

(j) crystallizing the compound of formula (V) using ethyl acetate and water to provide a crystalline form of the compound of formula (V); and

(k) recrystallizing the crystalline form of the compound of formula (V) using ethyl acetate and water to provide a pharmaceutical material comprising a purified amount of the compound of formula (V).

34. The method of claim 33 wherein in step (g), extracting the compound of formula (V) from the solution using methyl tert-butyl ether is conducted at a temperature less than or equal to about 50 °C.

35. The method of claim 33 or 34, wherein in step (j), crystallizing the compound of formula (V) using ethyl acetate and water is conducted over a temperature range of about 50 °C to about -5 °C.

36. The method of any one of claims 33-35, wherein in step (k), recrystallizing the crystalline form of the compound of formula (V) using ethyl acetate and water is conducted over a temperature range of about 70 °C to about 5 °C.

37. The method of any one of claims 33-36, further comprising:

(l) dissolving the crystalline form of the compound of formula (V) in acetonitrile, thereby forming a solution;

(m) contacting the solution with charcoal;


(n) filtering the charcoal to provide a purified solution comprising the compound of formula (V); and

(o) crystallizing the compound of formula (V) from the purified solution to provide a

pharmaceutical material comprising a purified amount of the compound of formula (V).

38. The method of any one of claims 33-37, wherein the purified amount of the compound of formula (V) is greater than 99.0% by weight of the total weight of the pharmaceutical material.

- 5 39. A pharmaceutical material comprising a crystalline form of the compound of formula (V):



or a pharmaceutically acceptable salt thereof;

- wherein the pharmaceutical material comprises the compound of formula (V), or a
 10 pharmaceutically acceptable salt thereof, in an amount greater than 99.0% by weight based on the total weight of the pharmaceutical material.

40. The pharmaceutical material of claim 39, wherein the crystalline form of the compound of formula (V) exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.3±0.2, 10.4±0.2, 17.9±0.2, 18.8±0.2, 19.5±0.2, and 20.7±0.2.

- 15 41. The pharmaceutical material of claim 39, wherein the crystalline form of the compound of formula (V) is characterized by the following X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ:

Angle [2θ]
5.2
10.3
10.4
11.8
13.7
15.5
15.6
17.3
17.6
17.9
18.8

Angle [2 θ]
19.5
19.7
20.4
20.7
21.1
22.0
22.6
23.1
23.6
23.9
24.7
25.8
26.3
27.5
29.2
30.2
30.8
31.3
31.9
32.9
34.4
35.1
36.2
37.2
37.9

42. The pharmaceutical material of any one of claims 39-41, wherein the crystalline form of the compound of formula (V) exists in a monoclinic crystal system and has a $P2_1/c$ space group.

43. The pharmaceutical material of claim 42, wherein the crystalline form of the compound of formula (V) is characterized by the following crystallographic unit cell parameters:

Unit cell dimensions	a = 17.9209(8) Å	$\alpha = 90^\circ$
	b = 9.8547(5) Å	$\beta = 106.834(10)^\circ$
	c = 12.2775(6)	$\gamma = 90^\circ$
Volume	2075.35 Å ³	
Z	4	
Density (calculated)	1.102 Mg/m ³	

44. The pharmaceutical material of any one of claims 39-43, wherein the crystalline form of the compound of formula (V) is characterized by an X-ray powder diffraction pattern substantially the same as shown in FIG. 4.

45. The pharmaceutical material of any one of claims 39-44, wherein the crystalline form of the compound of formula (V) has a melting point onset as determined by differential scanning calorimetry in the range of from about 90 °C to about 94 °C.

46. The pharmaceutical material of claim 45, wherein the crystalline form of the compound of formula (V) has a melting point onset as determined by differential scanning calorimetry at about 92 °C.

47. The pharmaceutical material of any one of claims 39-46, wherein the crystalline form of the compound of formula (V) has a differential scanning calorimetry curve substantially the same as shown in FIG. 5.

48. The pharmaceutical material of any one of claims 39-47, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.5% by weight based on the total weight of the pharmaceutical material.

49. The pharmaceutical material of any one of claims 39-48, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.7% by weight based on the total weight of the pharmaceutical material.


50. The pharmaceutical material of any one of claims 39-49, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.9% by weight

based on the total weight of the pharmaceutical material.

51. The pharmaceutical material of any one of claims 39-50, wherein the pharmaceutical material comprises the compound of formula (V) in an amount of from about 98% to about 102% by weight based on the total weight of the pharmaceutical material, as determined by a high performance liquid chromatography (HPLC) assay.

52. The pharmaceutical material of claim 51, wherein the HPLC assay uses a Waters XBridge BEH C18 column (4.6 mm i.d. x 150 mm, 2.5 μ m) at a temperature of about 40 °C, with isocratic elution of a mobile phase comprising about 0.05% phosphoric acid in water/acetonitrile (about 50:50) at a flow rate of about 1.2 mL/minute, and detection at 215 nm, wherein the retention time of the compound of formula (V) is about 4.6 minutes.


53. The pharmaceutical material of any one of claims 39-52, further comprising a compound of formula (VI):



or a pharmaceutically acceptable salt thereof.

54. The pharmaceutical material of claim 53, wherein the pharmaceutical material comprises the compound of formula (IX), or a pharmaceutically acceptable salt thereof, in an amount no greater than about 0.15% by weight based on the total weight of the pharmaceutical material.

55. The pharmaceutical material of any one of claims 40-54, further comprising a compound of formula (VII):



or a pharmaceutically acceptable salt thereof.

56. The pharmaceutical material of claim 55, wherein the pharmaceutical material comprises the compound of formula (VII), or a pharmaceutically acceptable salt thereof, in an amount no greater than about 0.15% by weight based on the total weight of the pharmaceutical material.

57. The pharmaceutical material of any one of claims 39-56, further comprising less than or equal to 0.2% by weight of unknown impurities.
58. A pharmaceutical formulation comprising:
the pharmaceutical material of any one of claims 39-57; and
5 a pharmaceutically acceptable excipient.
59. A method of treating a disease or a condition as described herein, the method comprising administering to a patient a therapeutically-effective amount of the pharmaceutical material of any one of claims 39-57, or of the pharmaceutical formulation of claim 58.
60. The method of claim 59, wherein the disease or condition is primary hyperlipidemia.
- 10 61. A method of treating primary hyperlipidemia in a patient in need thereof, the method comprising administering to a patient a therapeutically-effective amount of the pharmaceutical material of any one of claims 39-57, or of the pharmaceutical formulation of claim 58.